* MGI Pharma Inc., of Minetonka, Minn., finalized an agreement toco-develop the anti-tumor compound MGI 114 with the NationalCancer Institute. The compound is from a family called acylfulvenes,which are derived from the jack-o'lantern mushroom.
* NeoTherapeutics Inc., of Newport Beach, Calif., said underwritersexercised an overallotment option on 200,000 units at $7.60 each,bringing gross proceeds from the initial public offering to $20.52million. The company is developing drugs that act on the centralnervous system.
(c) 1997 American Health Consultants. All rights reserved.